🇺🇸 FDA
Pipeline program

PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

ACT16146

Phase 2 small_molecule active

Quick answer

PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Cancer is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials